Amarin Receives Patent Allowance for App Related to Vascepa, FDA-Approved MARINE
Amarin Corporation plc (Nasdaq: AMRN) announced today that the US PTO has published notification of Notice of Allowance for U.S. Patent Application Serial Number 13/608,775. This application includes claims intended to protect the Vascepa^® (icosapent ethyl) indication approved in July 2012 by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical trial results. This application is a continuation of Amarin's U.S. Patent Number 8,293,728 (formerly, the '153 application) and broadens the '728 claims by covering the use of Vascepa with and without other lipid lowering agents, such as statins. The '775 application claims gauge drug effects against placebo control.
A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would have a term that expires no earlier than in 2030. After issuance, Amarin plans to list this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.